Third Rock, SV bankroll an­oth­er PhI/II for a new, im­proved and jab-free wet AMD drug

More than three years af­ter rais­ing a $45 mil­lion B round to get its lead drug in­to the clin­ic for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, two of PanOp­ti­ca’s in­vestors have come back with an $11 mil­lion add-on to do some more Phase I/II work with what they’re call­ing a next-gen for­mu­la­tion.

Third Rock and SV Health In­vestors are pro­vid­ing the Se­ries B(b) funds to get a top­i­cal drug back in­to the clin­ic. In the first try at the Bernardsville, NJ-based biotech, re­searchers say they got a pos­i­tive bi­o­log­i­cal re­sponse in about half of the pa­tients. But there clear­ly must have been some short­com­ings with corneal tox­i­c­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.